|GenoMed Joins International Disease Management Alliance|
ST. LOUIS--(July 13, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that it has joined the International Disease Management Alliance (IDMA) recently organized by Warren E. Todd, the group's founder and Executive Director.
The IDMA (www.dmalliance.org) was formed to promote the concept of Disease Management around the world. As the only healthcare strategy that both improves patient outcomes and reduces healthcare costs, Disease Management has as much appeal globally as it does in the United States.
Said Warren E. Todd, Executive Director for IDMA, "We're delighted to welcome GenoMed to the Alliance and applaud their recognition of the international potential for disease management . Genomics provides a differentiated approach to disease management that should be well received in countries where more physician-centric models of disease management are common."
GenoMed's CEO, David Moskowitz MD, said, "We are thrilled to be one of the first Institutional members of the new IDMA and look forward to supporting the global expansion. Warren Todd is famous as one of the founders of the Disease Management industry in the U.S., and now around the world. We've long believed that our Next Generation DM(tm) business model would resonate especially well with capitated health plans, such as National Health Services in Canada, Europe, Japan, the United Kingdom, and other Commonwealth countries. GenoMed's membership in the IDMA should provide us with an entree to the global healthcare market. Our reliance on the Internet rather than telephone call centers, and our novel physician-oriented business model, give us a global reach immediately."
Added Dr. Moskowitz, "Rising healthcare costs have already reached a crisis point in the U.S. Medicaid programs in many states have begun disenrolling patients to lower costs. Many of these patients will soon die for lack of medications. The best way to control healthcare costs is to control diseases and cut back on hospitalizations. Only genomics-based medicine can do this. And only GenoMed has demonstrated that it can halt cardiovascular diseases including emphysema."
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema.
David Moskowitz MD FACP